Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative disorders, fibrotic diseases, and inflammatory conditions. This page serves as the definitive source for verified corporate developments, offering investors and researchers timely access to essential information.
Find comprehensive coverage of MNOV's clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on lead candidates MN-166 (ibudilast) and MN-001 (tipelukast), patent developments, and collaborative research initiatives with academic institutions.
Key content categories include clinical program updates, FDA communications, intellectual property announcements, and financial disclosures. All materials are sourced directly from company filings and official statements to ensure accuracy.
Bookmark this page for streamlined tracking of MNOV's progress in developing small-molecule therapeutics. Check regularly for updates on pipeline advancements in ALS, multiple sclerosis, and fibrotic disease research.
MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the randomized, placebo-controlled Phase 2 OXTOX study evaluating MN-166 (ibudilast) to prevent chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer.
A total of 100 patients were randomized across two arms at 11 clinical sites in Australia. Patient recruitment is closed; participants continue chemotherapy with assigned study drug until disease progression or unacceptable toxicity. The study will conclude when the final patient reaches six months post-chemotherapy. Top-line data are anticipated later in 2026, though no exact completion date is provided.
MediciNova (NASDAQ:MNOV) reported an update from the COMBAT-ALS Phase 2b/3 trial of MN-166 (ibudilast) presented at the 36th International Symposium on ALS/MND (Dec 5–7, 2025).
Key facts: 234 participants randomized, enrollment completed Sept 2025. Baseline metrics: mean age 60.6, mean ALSFRS-R 40.6, mean disease duration 12.5 months. Sex split: 36.8% female, 63.2% male. Racial mix: Caucasian 90.2%, Asian 5.1%.
The company noted COVID-19–related enrollment challenges, is offering continued access via FDA individual expanded access, and cited FDA Orphan Drug and Fast Track designations and European orphan designation. Top-line data are anticipated by end of 2026.
MediciNova (MNOV) reported a peer-reviewed publication showing MN-002, the primary metabolite of MN-001, increases cholesterol efflux by upregulating ABCA1 and ABCG1 in macrophages, a mechanism tied to Reverse Cholesterol Transport.
The company completed patient enrollment in its Phase 2 MN-001-NATG-202 randomized, double-blind, placebo-controlled trial in hypertriglyceridemia and NAFLD due to T2DM; top-line results are expected by summer 2026. Management says the mechanistic data reinforce prior clinical lipid-profile observations and will inform next steps toward advancing MN-001 as a potential first-in-class therapy for metabolic and cardiovascular disease.
MediciNova (NASDAQ:MNOV) announced on November 18, 2025 the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova’s drug development programs and will lead the Scientific Advisory Board upon its formation.
Dr. Breder brings over two decades of regulatory and clinical experience, including more than a decade at the FDA as Medical Officer and Lead Medical Officer, involvement in NDA review and safety analysis training, and participation in reviews and initial approvals for therapies targeting ALS, myasthenia gravis, and Duchenne muscular dystrophy. He holds an MD and PhD from the University of Chicago and completed clinical training at Johns Hopkins Hospital.
MediciNova (NASDAQ:MNOV) announced on November 6, 2025 that it won the Contract Research and Development Innovation Award at the Fifth Annual BioTech Breakthrough Awards.
The award recognizes MediciNova's work advancing MN-166 (ibudilast), its lead small-molecule candidate in development for multiple neurological diseases including ALS. The company noted ongoing progress in the Phase 2/3 COMBAT-ALS trial and said the recognition highlights its focus on neuroinflammation modulation and neuroprotection as a potential disease-modifying approach.
MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) for hypertriglyceridemia and NAFLD due to Type 2 diabetes.
The multi-center, randomized, double-blind, placebo-controlled study randomizes patients 1:1 to 500 mg/day MN-001 or placebo for 24 weeks. Co-primary endpoints are change in liver fat by CAP score and change in fasting serum triglycerides at Week 24. Secondary endpoints include safety, tolerability, and changes in HDL-C, LDL-C, and total cholesterol. Patient recruitment is closed and top-line data are expected by summer 2026.
MediciNova (NASDAQ:MNOV) announced a peer-reviewed study published Oct 30, 2025 showing that MN-002, the primary metabolite of investigational tipelukast (MN-001), enhanced cholesterol efflux in macrophages by upregulating transport proteins ABCA1 and ABCG1. The research, conducted with a Japanese academic group and published in the Journal of Atherosclerosis and Thrombosis, suggests a novel mechanism of action and a potential therapeutic strategy for atherosclerosis and metabolic disorders.
MediciNova said MN-001 is an oral small molecule with anti-inflammatory and anti-fibrotic properties, prior clinical studies showed improved serum lipid profiles in NAFLD and hypertriglyceridemia patients, and a randomized double-blind Phase 2 study in hypertriglyceridemia, type 2 diabetes, and NAFLD is nearing enrollment completion.
MediciNova (NASDAQ: MNOV) will present a corporate overview at the LD Micro Main Event XIX in San Diego on Monday, October 20, 2025 at 1:30 PM PT. Presenters are Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer.
A live webcast will be available via the company's investor relations website and a replay will be archived for 90 days. The presenters will be available for one-on-one meetings during the conference (October 19–22, 2025).
MediciNova (NASDAQ:MNOV) has completed patient enrollment in its Phase 2b/3 COMBAT-ALS clinical trial evaluating MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis (ALS) treatment. The study has successfully randomized 234 patients across sites in the United States and Canada.
The trial is designed as a randomized, double-blind, placebo-controlled study with a 12-month treatment period followed by a 6-month open-label extension. The primary endpoint focuses on the Combined Assessment of Function and Survival (CAFS), with top-line data expected by end of 2026.
MN-166 has received Orphan Drug and Fast Track Designations from the FDA and Orphan Designation from the EMA, having shown promising results in earlier studies.
MediciNova (NASDAQ:MNOV) announced that its Phase 2b/3 COMBAT-ALS clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients will be featured in a poster presentation at the 36th International Symposium on ALS/MND. The symposium will take place from December 5-7, 2025 in San Diego, CA.
The presentation, titled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Baseline Characteristics," has been assigned Paper Number 228 and falls under the Clinical Trial and Trial Design theme.
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
